Adaptimmune, a British-based biotech company born out of the University of Oxford has a solid research base in the UK and manufactures its T-Cells in the US. Its CEO, James Noble, shares Adaptimmune’s story and explains why regulatory support is essential in a field as complex and novel as T-Cell therapies.
James, what was your passion for cell therapy and the biotech industry at large born out of?
"The regulatory environment we encountered has been unbelievably helpful ... To us, a good relationship with authorities, based on dialogue and understanding is essential, because it is the guarantee for a continuous discussion."
